Experts in Preimplantation Genetic Diagnosis

As Reprogenetics VP of Finance Jack brings more than 20 years experience in senior finance and operations roles with an in-depth understanding of healthcare and healthcare technology. His experience includes over 18 years working closely with managed care, regulatory compliance, pharmacy and lab services and physician practices focused on fertility. With an MBA and CPA Jack also oversees accounting and finance functions including treasury, regulatory compliance M&A, planning and reporting.

Prior to joining Reprogenetics, he served as CFO & COO of Mystique Brands, LLC, a consumer branding company based in Manhattan. He was recruited by Mystique’s venture-backed investors as part of a new management team early in 2007 to turn around the start-up. Following the strategies he developed, Mystique underwent a restructuring that include recruiting a new CEO and adding eleven new labels to its portfolio of premium brands and products, relocated its headquarters, replaced most of the sales force and raised a second round of capital. Jack was also instrumental in ensuring compliance with NY EDA programs resulting in significant tax savings.

In 2003, Jack joined WIN Healthcare (dba WinFertility), a healthcare services company based in Westchester, NY and specializing in managed care fertility management in a financial consulting role which evolved into the position of CFO and senior vice president. In addition to accounting and treasury functions, Jack’s responsibilities included provider and plan contracting and compliance as well as claims processing and human resources.

Jack is a CPA with a BS from Villanova and holds an MBA from Monmouth University. He has a strong background in healthcare and technology services, and has served as CFO of Physical Acoustics Corporation (PAC) in Princeton, NJ, CFO of NASDAQ listed Ariel Corporation in Cranbury, NJ, and eleven years with Concurrent Computer Corporation in Oceanport, NJ in roles of increasing management responsibility both before and after Concurrent’s IPO spin-off from Perkin-Elmer Corporation.